Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that 6-Gingerol significantly suppressed hair growth in mice by reducing hair follicle number and length, potentially through increased expression of MMP2 and MMP9.

This review summarizes therapeutic advances reported in English-language literature from December 1987 to December 1988 and states no new clinical results.

In this case report, treatment with anifrolumab led to significant improvement in symptoms for a 52-year-old woman with refractory systemic lupus erythematosus, including resolution of chronic lupus headaches resistant to previous therapies.

This article reviews the therapeutic use of interferons and other cytokines in various viral, tumorous, and inflammatory diseases, discussing their biological effects and potential future applications without presenting new experimental results.

This study found that cutaneous ulcers caused by interferon are not associated with the medication's dosage.

During treatment with interferon/ribavirin for hepatitis C, this study observed significant and lasting improvement in a patient's psoriasis without additional psoriasis-specific therapies.

In this clinical trial, patients with lichen planopilaris treated with the oral TYK2 inhibitor deucravacitinib showed significant improvement in PGA, LPPAI, and Skindex-16 scores over 24 weeks, with transcriptomic analyses indicating decreased inflammatory and immune pathway activity post-treatment.

In this study, nearly 5% of anti-TNF-treated patients with IBD developed psoriasiform skin lesions, with smoking identified as a main risk factor, and ustekinumab proved highly effective in severe cases.

This study found that recombinant human leukocyte interferon alfa-2a achieved a 64% overall antitumor response rate in patients with early and advanced cutaneous T cell lymphoma and was generally well-tolerated.

This study found that injecting interferon gamma into C3H/HeJ mice did not alter the frequency or onset of alopecia areata, suggesting the protein alone does not trigger the disease.

In this study, pegylated interferon alfa-2b injections led to local cutaneous reactions, including cutaneous necrosis, in patients with hepatitis C and chronic myelocytic leukemia, requiring dose modifications or treatment withdrawal in some cases.

This study found that intralesional triamcinolone acetonide was most effective for hair regrowth in localized alopecia areata, with betamethasone valerate foam also being beneficial, while tacrolimus ointment showed no significant effect.

This study found that the once-daily gel combining calcipotriene and betamethasone dipropionate was more effective and faster in treating scalp psoriasis compared to individual treatments, with a similar safety profile.

In this study, Typhonium flagelliforme leaf-ethanolic extract combined with natural interferon was observed to stabilize body weight, inhibit tumor growth, and reduce mitosis, angiogenesis, and certain protein expressions in carcinogen-induced tumors in female mice, suggesting potential antitumor effects.

This study observed that Betamethasone oral mini-pulse therapy showed a good response in 60% of lichen planus patients, though further research is needed to confirm its efficacy.

This review discusses the uncommon but potentially serious cutaneous reactions to beta-adrenergic blockers and the uncertain pathogenesis, with no new clinical results reported.

In this study, patients with alopecia areata experienced significant hair regrowth using topical latanoprost, minoxidil, or betamethasone valerate, with the addition of latanoprost enhancing the effectiveness of betamethasone valerate, showcasing these treatments as safe and effective options.

This study observed that topical dinitrochlorobenzene was significantly more effective than topical betamethasone in treating patients with alopecia areata, with 53.3% achieving excellent hair regrowth compared to 13.3% using betamethasone.

This study demonstrated the expression of type 1 interferon-related proteins in inflammatory lesions of alopecia areata, showing a distinct distribution pattern compared to cicatricial alopecia.

This study observed that two patients treated with interferon α-2b and ribavirin for chronic hepatitis C experienced complete and reversible straightening of their natural curly hair, which recurred with treatment resumption.

This review highlights LTBP1 as a critical integrator in disease processes, showing its dual role in cancer progression and suppression, its pathological influence in fibrosis, and its contribution to various disorders, suggesting its potential as a biomarker and therapeutic target.

This study explores potential strategies for targeted drug delivery specifically to pancreatic beta-cells in type 2 diabetes treatment, highlighting methods for inducing drug expression in beta-cells, suitable drug carriers, active targeting peptides, and optimal administration routes.

This study found that certain nutraceuticals did not interfere with tamoxifen's inhibition of estrogen in breast cancer cells and may enhance its effects, suggesting potential as an adjuvant therapy for hair loss in patients undergoing endocrine therapy.

This letter to the editor discusses a potential link between new onset alopecia areata and SARS-CoV-2 infection, but reports no new clinical results.

This study found that androgen metabolism within hair follicles varies significantly between compartments, with dermal papillae showing high 5α-reductase activity, suggesting a key role in androgen-driven hair growth responses.

This review discusses various presentations of drug-induced cutaneous eruptions, particularly those associated with interferon and ribavirin, and reports no new clinical findings.

Some drugs can cause hair loss, and stopping these drugs often leads to hair regrowth.

This study suggests that the neuropeptide CGRP may protect against, but not restore, IFNγ-induced collapse of hair follicle immune privilege in alopecia areata.

This article discusses the potential of oral tofacitinib as a treatment for atopic dermatitis, alopecia areata, and vitiligo, without presenting new clinical results.

This study suggests that mesenchymal stem cell therapy may improve cell viability and regulate key signaling pathways in vitro for treating alopecia areata.